GS
SAGE

George Soros’s Sage Therapeutics SAGE Stock Holding History

George Soros’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-275,000
Closed -$5.15M – 220
2024
Q1 		$5.15M Buy
+275,000
New +$6.34M 0.09% 147

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

George Soros's SAGE Position: Q2 2024 in Review

George Soros sold out of Sage Therapeutics (SAGE) in Q2 2024, closing a stake of 275,000 shares — an estimated $5.15M sold.

George Soros first reported a position in SAGE in Q1 2024 and held it in 1 quarter. The position peaked at $5.15M in Q1 2024. 195 funds tracked by Wall St. Rank hold SAGE as of Q2 2024.

  • George Soros reported no remaining Sage Therapeutics position as of Q2 2024 after selling out during the quarter.
  • George Soros sold 275,000 Sage Therapeutics shares in Q2 2024, an estimated $5.15M.
  • George Soros first reported a position in Sage Therapeutics in Q1 2024 and held it in 1 quarter.
  • George Soros's Sage Therapeutics position peaked at $5.15M in Q1 2024.
  • 195 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2024.

Based on Soros Fund Management's 13F filing for Q2 2024, filed 14 Aug 2024.